Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
corabotase
- Development stage
- Phase 3
- Lead developer
- Ipsen
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Corabotase (IPN10200) is a recombinant botulinum toxin type A (BoNT/A) developed by Ipsen for aesthetic applications. Unlike conventional botulinum toxins that are purified from *Clostridium botulinum* cultures, corabotase is produced using a recombinant expression system, which allows for high precision in molecular design and manufacturing consistency. The drug functions as a zinc-dependent endopeptidase that enters peripheral cholinergic nerve terminals and selectively cleaves the synaptosomal-associated protein 25 (SNAP-25). This cleavage prevents the formation of the SNARE complex, thereby blocking the exocytosis of acetylcholine into the synaptic cleft. The resulting chemical denervation causes localized, reversible muscle paralysis, which is utilized to smooth upper facial lines, including glabellar, forehead, and lateral canthal lines. Corabotase is currently in Phase 3 clinical development, representing a next-generation approach to neuromodulator therapy in medical aesthetics.
- Brand names
- Dysport NG
- Other names
- recombinant botulinum toxin type ArBoNT/A
02
Targets
SNAP25 (Synaptosome-associated protein 25)
Beyond the preview
Go deeper on corabotase.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on corabotase.